Sellas Life Sciences stock draws attention after BlackRock discloses 7.9% stake

what happened

According to Stocktwits, Sellas Life Sciences (SLS) shares rose 7% on Tuesday, closing at $12.17. The move followed a BlackRock disclosure: in a Tuesday filing, the fund reported holding 15.87 million shares as of September 30. That is about 31% more than the 12.14 million shares it held at the end of March.

Interest has also been fueled by European forecasts for possible approval of GPS, the company's leukemia immunotherapy. An Austrian health-technology assessment report lists November 1, 2027 as the expected European Commission approval date, while a Dutch Medicines Horizon Scan entry gives April 2027 as expected registration. The Austrian report itself warns that such timelines carry uncertainty.

The key event is the Phase 3 REGAL trial. The final analysis will be triggered by the 80th death across treatment groups, and the latest disclosed count was 78 events as of May 11. Sellas says it will announce the 80th event, but it remains blinded to efficacy and survival outcomes. Retail sentiment on Stocktwits has shifted from bullish to neutral over the past week.

why it matters

For Sellas, the main driver is the Phase 3 GPS data and the SLS009 study, not the disclosure of one large holder. The BlackRock filing is routine reporting on major owners, but it shows institutional interest ahead of results. The shares are up 223% year to date, so the reaction to the data could be sharp in either direction.

tags

instruments